Muhimbili University of Health And Allied Sciences
Dar es Salaam, PO BOX 65001, Tanzania
NCT Number: NCT01119612
The purpose of this study is to determine safety and efficacy of prenatal iron supplementation in an area of high malaria burden among women who are not anemic or iron deficient.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Dar es Salaam, PO BOX 65001, Tanzania
Iron deficiency anemia and malaria are urgent public health problems in sub-Saharan Africa, including Tanzania. There is a paucity of good quality randomized trials assessing the safety and efficacy of iron supplementation in pregnancy, and its effects on perinatal health outcomes. Prenatal iron supplementation is recommended based on its demonstrated benefit in preventing and treating maternal anemia. There is limited data on the efficacy of iron supplementation on pregnancy outcomes, including birth weight. There are also concerns regarding the use of iron supplementation, particularly among non-anemic women. In particular, there is a lack of research on the safety and efficacy of prenatal iron supplementation in developing regions, characterized by extensive burden of iron deficiency, malaria, and other endemic infectious diseases. Evidence from randomized controlled trials is urgently needed to examine the safety and efficacy of iron supplements among pregnant women in malaria endemic regions, particularly among women who are not anemic.
NOTE: The time frames listed for the maternal malaria and hemoglobin outcomes were updated on 4/22/15. This record initially indicated that maternal malaria anemia and hemoglobin would be measured at several specific time points throughout the study. Instead, maternal malaria was measured throughout pregnancy and hemoglobin was measured only at delivery. Due to an oversight, we did not update this record when this protocol change took effect at the start of the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily oral dose of 60 mg from enrollment until delivery
Daily oral dose from enrollment until delivery
Time frame: Delivery
Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.
Time frame: Delivery
Placental malaria parasite density will be defined as number of parasites per μL of blood or 200 white blood cells; the latter will be converted to a count per μL of blood assuming a count of 8000 WBC/μL.
Time frame: Delivery
Continuous measurement
Time frame: Delivery
Continuous measurement
Time frame: Delivery
Low birth weight will be defined as birth weight less than 2500 grams.
Time frame: During pregnancy
Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.
Time frame: Delivery
Anemia will be defined as hemoglobin less than 11 g/dl. Severe anemia will be defined as less than 8.5 g/dl.
Harvard School of Public Health (HSPH)
Other
Acronym: MAL1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03897673
Anemia, Anemia in Children
Kampala, Uganda
View Trial DetailsNCT03931473
Anemia, Hematologic Diseases
Cové, Benin
View Trial DetailsNCT04858087
Anemia, Hematologic Diseases
View Trial DetailsNCT00367380
Anemia, Body Temperature Changes
Cali, Valle del Cauca Department, Colombia
View Trial Details